Xgeva Use in Myeloma May Be Expanded to Europe Following Positive CHMP Opinion
Treatment of bone lesions in multiple myeloma patients with Amgen’s Xgeva (denosumab) may be expanded to European patients following a positive opinion from…
Myeloma
Revlimid Combo Treatment Improved Survival in Newly-diagnosed Myeloma Patients in Phase 3 Trial
Newly diagnosed multiple myeloma patients unable to undergo stem cell transplants lived significantly longer without their disease progressing when given continuous treatment with…
UT Southwestern Researcher Tells His CAR-T Therapy Story Ahead of Myeloma Trial
As UT Southwestern and Celgene Corporation join efforts to launch a new clinical trial to evaluate a chimeric antigen receptor T-cell therapy,…
Adelson Research Foundation Supports 3-Year Myeloma Funding Initiative
The Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF), a private organization funding collaborative translational science, recently launched the Adelson Program in…
Pomalyst Combo Delays Disease Progression in Relapsed or Refractory Myeloma Patients in Phase 3 Trial
A combination treatment including Pomalyst (pomalidomide) significantly extended the time until disease progression or death in patients with relapsed or refractory multiple myeloma who were…
PT-112 Receives Orphan Drug Status for Advanced Multiple Myeloma
PT-112, an investigational small molecule that promotes cancer cell death, has been designated an orphan drug by the U.S. Food and Drug Administration (FDA) for…
Most Canadians Wouldn’t Know Where to Turn If Diagnosed With Blood Cancer, Survey Finds
Some 68 percent of Canadians would feel helpless if they or someone close to them received a blood cancer diagnosis, found a recent poll commissioned…
Multiple Myeloma Patients in UK Gain Access to Ninlaro through Cancer Drugs Fund
Multiple myeloma patients in the United Kingdom can now potentially benefit from a new oral pill sold as Ninlaro…
Stem Cell Transplants Better Than New Therapies at Delaying Myeloma Progression, Analysis Finds
In an era of new therapies with unprecedented efficacy, high-dose therapy with melphalan followed by autologous stem cell transplant (HDT/ASCT) is still associated with better progression-free…
Ethyol Pretreatment Reduces Gastrointestinal Side Effects of Bone Marrow Transplant in Myeloma Patients
Pretreating multiple myeloma patients with Ethyol (amifostine) prior to a stem cell transplant significantly reduces the transplant therapy’s gastrointestinal toxicity without compromising its efficacy, a…
Recent Posts
- Germany clears pelareorep pancreatic cancer trial continuation
- FDA grants orphan drug status to novel brain cancer treatment
- Medicaid expansion can raise demand for gynecologic cancer care
- Under-the-skin Sarclisa found as effective as approved formulation
- FDA gives LYT-200 fast track status as potential AML treatment